Biotechnology: Biological Products (No Diagnostic Substances)

Board MeetingApr 24, 2026, 04:03 PM

Compass Therapeutics to Host Webcast on Phase 2/3 BTC Study Results

AI Summary

Compass Therapeutics, Inc. announced it will host a webcast on Monday, April 27, 2026, at 8:00 AM ET. The event will review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study. This study evaluates tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer, providing an important update on their clinical pipeline.

Key Highlights

Webcast scheduled for April 27, 2026, at 8:00 AM ET.
To review topline secondary endpoints from Phase 2/3 COMPANION-002 study.
Study assesses tovecimig in advanced biliary tract cancer.

View SEC Filing

CMPX

Biotechnology: Biological Products (No Diagnostic Substances)

Compass Therapeutics, Inc.

Price Impact